2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1601

Evaluation of Glucose Metabolism in Rheumatic Patients: A Case Control Study
Abstract Number: 3089

Evaluation of Learned Helplessness, Perceived Self-Efficacy and Functional Capacity in Patients with Fibromyalgia and Rheumatoid Arthritis
Abstract Number: 3050

Evaluation of Olfactory Function in Behcet’s Disease
Abstract Number: 684

Evaluation of Patient Acceptable Symptom State in Patients with Axial Spondylarthritis; Similar Thresholds for Radiographic and Non-Radiographic Subgroups
Abstract Number: 2748

Evaluation of Patient-Reported Outcomes By Baseline Disease Duration: 6-Month Data from Two Clinical Trials of Patients with Early Rheumatoid Arthritis Treated with Abatacept
Abstract Number: 620

Evaluation of Patients from the Non-Biologic Arms of Inflammatory Arthritis Clinical Trials Identifies Several Predictors of Remission, As Well As, Distinct Responder Subgroups
Abstract Number: 506

Evaluation of Persistence and Outcomes in Patients Treated with TNF and Non-TNF Biologics Following Treatment Clinical Pathway in Rheumatoid Arthritis
Abstract Number: 3055

Evaluation of Plasma Pentraxin-3 Level in Patients with Takayasu’s Arteritis
Abstract Number: 3210

Evaluation of Sacroiliac Joint Radiographs in Patients with Chronic Low Back Pain: Is Erosion the Main Driver of Interreader Disagreement?
Abstract Number: 2991

Evaluation of Serum Levels of Adipokines and Interleukines in Pericardial Effusion Related to Systemic Sclerosis
Abstract Number: 2604

Evaluation of Serum Undercarboxylated Osteocalcin in Premenopausal Rheumatoid Arthritis Patients; Its Correlation with Disease Activity and Bone Mineral Density
Abstract Number: 769

Evaluation of Soluble Alpha-Klotho in Neuropsychiatric Systemic Lupus Erythematosus
Abstract Number: 2996

Evaluation of Systemic Sclerosis Risk Genes in the Turkish Population
Abstract Number: 562

Evaluation of T Helper Cell 1(Th1) – and T Helper Cell 17(Th17) – Associated Chemokines As Prognostic Biomarkers for Tumor Necrosis Factor (TNF) Inhibitor Therapy in Rheumatoid Arthritis (RA)
Abstract Number: 930

Evaluation of Temporomandibular Joint Arthritis with Ultrasound in Juvenile Idiopathic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].